Showing results (1-10 of 152) with videos related to

Sort By:
Pageof 16
Expert Review of Gastroenterology & Hepatology|December 1, 2017
Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis CHope Hubbard, Eric Lawitz
Hepatology Communications|July 21, 2018
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetesNaim Alkhouri, Fred Poordad, Eric Lawitz
Current Opinion in Pharmacology|November 10, 2017
Novel treatments for chronic hepatitis C: closing the remaining gapsNaim Alkhouri, Eric Lawitz, Fred Poordad
Hepatology Communications|May 8, 2019
Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH TreatmentNaim Alkhouri, Eric Lawitz, Mazen Noureddin
Clinics in Liver Disease|October 16, 2015
Next-Generation Regimens: The Future of Hepatitis C Virus TherapyJohn Vizuete, Hope Hubbard, Eric Lawitz
Expert Opinion on Investigational Drugs|September 15, 2019
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)Naim Alkhouri, Eric Lawitz, Mazen Noureddin, et al.
Clinical and Molecular Hepatology|August 4, 2025
Prospects of Late-Stage Development Agents in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)Brian Lee, Ussama Ghumman, Lisa D Pedicone, et al.
Clinical Pharmacology in Drug Development|November 1, 2023
Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic ImpairmentEric Lawitz, Deven Parmar, Taufik Momin, et al.
Pageof 16